GCP
ENSC icon

GSA Capital Partners’s Ensysce Biosciences ENSC Stock Holding History

GSA Capital Partners’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,170
Closed -$32K – 1604
2023
Q2 		$32K Buy
+1,170
New +$52.9K ﹤0.01% 1433

Other funds holding ENSC

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GSA Capital Partners's ENSC Position: Q3 2023 in Review

GSA Capital Partners sold out of Ensysce Biosciences (ENSC) in Q3 2023, closing a stake of 1,170 shares — an estimated $32K sold.

GSA Capital Partners first reported a position in ENSC in Q2 2023 and held it in 1 quarter. The position peaked at $32K in Q2 2023. 12 funds tracked by Wall St. Rank hold ENSC as of Q3 2023.

  • GSA Capital Partners reported no remaining Ensysce Biosciences position as of Q3 2023 after selling out during the quarter.
  • GSA Capital Partners sold 1,170 Ensysce Biosciences shares in Q3 2023, an estimated $32K.
  • GSA Capital Partners first reported a position in Ensysce Biosciences in Q2 2023 and held it in 1 quarter.
  • GSA Capital Partners's Ensysce Biosciences position peaked at $32K in Q2 2023.
  • 12 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q3 2023.

Based on GSA Capital Partners's 13F filing for Q3 2023, filed 15 Nov 2023.